Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
17 evidence topics · 15 sources
Warnings and precautions
FDA-approved prescribing information, boxed warning, contraindications, and REMS
Treatment-emergent and treatment-related adverse events: phase 1/2 monotherapy at 60 and 120 mg
“Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events by dose: posted registry results of the phase 1/2 trial
| Adverse event, affected/at risk (%) | 60 mg QD | 90 mg QD | 120 mg QD | 300 mg QD |
|---|---|---|---|---|
| Total serious adverse events | “4/33 (12.12%)” | “2/6 (33.33%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Febrile neutropenia (serious) | “0/33 (0.00%)” | “0/6 (0.00%)” | “2/83 (2.41%)” | “1/7 (14.29%)” |
| Nausea | “14/33 (42.42%)” | “2/6 (33.33%)” | “55/83 (66.27%)” | “6/7 (85.71%)” |
| Vomiting | “5/33 (15.15%)” | “1/6 (16.67%)” | “24/83 (28.92%)” | “5/7 (71.43%)” |
| Diarrhoea | “6/33 (18.18%)” | “0/6 (0.00%)” | “14/83 (16.87%)” | “1/7 (14.29%)” |
| Fatigue | “13/33 (39.39%)” | “0/6 (0.00%)” | “24/83 (28.92%)” | “4/7 (57.14%)” |
| Neutrophil count decreased | “2/33 (6.06%)” | “0/6 (0.00%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Alanine aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “11/83 (13.25%)” | “1/7 (14.29%)” |
| Aspartate aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “13/83 (15.66%)” | “0/7 (0.00%)” |
| Sinus bradycardia | “0/33 (0.00%)” | “0/6 (0.00%)” | “7/83 (8.43%)” | “2/7 (28.57%)” |
| Photopsia | “0/33 (0.00%)” | “2/6 (33.33%)” | “5/83 (6.02%)” | “3/7 (42.86%)” |
Neutropenia: phase 1/2 monotherapy
“Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neutropenia, albeit at a lower frequency, has also been reported with fulvestrant, with grade ≥ 3 neutropenia observed in 1% to 2% of patients receiving fulvestrant monotherapy and rates of febrile neutropenia of 0 to 1% [30, 31].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neutropenia: blood count monitoring in ongoing trials
“All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events including neutropenia: combination with ribociclib
| Related TEAE, n (%) | 120 mg + ribociclib, all grades (n = 56) | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg + ribociclib, all grades (n = 16) | 90 mg, grade 3 | 90 mg, grade 4 |
|---|---|---|---|---|---|---|
| Neutropenia | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| WBC decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |
Adverse events including neutropenia: combination with palbociclib
Bradycardia and photopsia: phase 1/2 monotherapy
“TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively) [25, 28, 29].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QTc interval: monotherapy and combination with ribociclib
“There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrointestinal toxicity: nausea, vomiting, and diarrhea
“The most frequently reported TRAEs were gastrointestinal events and fatigue, which have also been commonly reported with SERDs and selective ER covalent antagonists (SERCAs) [24–27].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic laboratory abnormalities
“In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| TEAE, 120 mg (n = 83) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All (%) |
|---|---|---|---|---|---|
| AST increased | “10” | “2” | “1” | “0” | “13 (16%)” |
Discontinuations due to adverse events: phase 1/2 monotherapy
“Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety assessments and independent data monitoring in OPERA-01
“Safety and tolerability (AEs, SAEs, dose modifications, clinical laboratory parameters, ECGs, performance status, and vital sign measurements)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent data monitoring committee (IDMC), comprising medical and statistical representatives not involved in the trial, is monitoring the safety, efficacy, and conduct of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote